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Head and neck cutaneous squamous cell carci-
noma (HNCSCC) is a growing problem in the
immunosuppressed population, and the behavior
of these cancers can be unexpectedly aggressive.
The role of adjuvant radiation therapy (RT) in the
management of high-risk HNCSCC has been an
area of much debate. We present a case of
HNCSCC with perineural invasion (PNI) success-
fully treated with surgery and adjuvant RT to
prevent recurrence.CASE REPORT
A 39-year-old man with a history of cystic fibrosis
underwent bilateral lung transplant in 2006 and was
taking prednisone, 5 mg daily, and tacrolimus, 3 mg
twice a day, for immunosuppression. He was treated
previously with Mohs micrographic surgery (MMS)
for multiple superficial head and neck skin cancers
and topical 5-fluorouracil cream (5%) for field dam-
age. He presented to the dermatology department
with a 3.2- x 2.5-cm nodular mass in the right pre-
auricular region composed of an erythematous
boggy plaque with central hemorrhagic crusts and
a posterior deeper nodular component slightly fixed
to the underlying surface closer to the tragus (Fig 1,
A). He denied any paresthesias or pain. No neck
lymphadenopathy was found on examination.
Computed tomography (CT) scan of the neck
confirmed a 3.2- 3 0.9- 3 1.9-cm plaquelike soft
tissue density of heterogeneous attenuation within
the cutaneous and subcutaneous fat overlying and
contiguous with the underlying parotid gland andthe Departments of Radiation Oncology and Dermatology,
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veland, OH 44195. E-mail: koyfmas@ccf.org.masseter muscle without distinct invasion. No
lymphadenopathy was seen (Fig 1, B).
The patient underwent radical resection of the
lesion with MMS, parotidectomy, and ipsilateral
supraomohyoid neck dissection with facial nerve
preservation and an anterolateral thigh free flap
reconstruction. The final histopathology found a 3-
cm moderately differentiated primary cutaneous
squamous cell carcinoma (SCC) with multifocal
PNI. None of the 15 nodes sampled had disease
(Fig 1, C ).
Given the multifocal PNI and his immunosup-
pressed state, the patient was treated with adjuvant
intensity-modulated RT (IMRT) to 58 Gy in 29
fractions (Fig 1, D). He had brisk radiation dermatitis
and moderate moist desquamation as well as fatigue
and taste changes. These symptoms resolved within
several months, and he is disease free at 21months of
follow-up, with no significant late adverse effects. He
continues to have multiple new superficial basal cell
carcinomas and SCCs, which have been managed
with MMS and topical 5-fluorouracil cream (5%). He
was weaned off tacrolimus, which was replaced with
sirolimus, 1.5 mg twice a day.JAAD Case Reports 2015;1:S5-7.
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Fig 1. A, Pre-auricular mass with overlying erythema. B, Axial section on contrast CT scan
shows a 3.2-3 0.9-3 1.9-cm plaquelike soft tissue density of heterogeneous attenuation within
the cutaneous and subcutaneous fat overlying and contiguous with the underlying right parotid
gland and masseter muscle without distinct invasion. No lymphadenopathy was seen.
C, Photomicrograph shows several peripheral nerve trunks with perineural carcinoma. An
associated lymphocytic inflammatory infiltrate surrounding the perineurium is present.D, Axial
(left panel) and coronal (right panel) sections on radiation planning CT scan show the
high-dose planning target volume (in red) and low-dose planning target volume in blue.
Isodose lines are depicted with 6000 cGy prescription line covering the high-dose target and
the 5400 cGy line covering the elective nodal target. The high-dose target includes branches
of the facial nerve as they track back toward the stylomastoid foramen. There is excellent
sparing of intracranial and midline organs at risk. (C, Hematoxylin-eosin stain; original
magnification: 312.)
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Immunosuppression from organ transplant is a
well-recognized risk factor and suspected prognostic
factor for skin cancer development.1 Several other
poor prognostic factors have been identified
including location (ear, lip, anogentital region), size
greater than 2 cm, greater than 4 mm depth of
invasion, PNI, poor differentiation, infiltrative/des-
moplastic growth pattern, local recurrence, and prior
radiation exposure.2 Surgery remains the primary
therapy for this disease. Radiation is an important
treatment modality either as adjuvant after surgery or
for unresectable or cosmetically challenging areas
and is often indicated in patients with these high-risk
features.
PNI occurs in 5% to 10% of patients with HNCSCC
and is a common indication for postoperative
radiotherapy.3 The extent of PNI is relevant, as focal
PNI has been associated with more favorableoutcomes. Although variably defined, patients with
isolated unifocal involvement of a small (\0.1 mm)
unnamed nerve may be safely observed. In a series
comprising predominantly patients treated with
resection and adjuvant RT, Lin et al3 found that focal
PNI was associated with improved relapse-free sur-
vival compared with extensive PNI (86% vs 74%;
P = .1). In addition to being associated with a 15% to
25% risk of local recurrence, some studies suggest
that the presence of PNI predicts for a higher
likelihood of nodal metastases as well, ranging
from 5% to 17% in varying studies, and serves as a
rationale for elective nodal irradiation in these
patients.4 In an Australian series, patients with
recurrent disease that had PNI at the time of
recurrence are at significantly higher risk of recur-
rence both locally (40% vs 19%; P \ .01) and
regionally (29% vs 5%; P = .02), and strong consid-
eration should be given to elective nodal irradiation
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currences in patients with clinically occult, patho-
logically determined microscopic PNI occurred in
the first-echelon lymph nodes.5 Patients with clini-
cally evident PNI, either owing to neurologic symp-
toms such as numbness, pain, or facial weakness or
radiographic evidence of nerve enhancement, have
inferior outcomes with locoregional control rates of
50% and cancer-related mortality rates as high as
40%.6 Radiographic evaluation of PNI should be
performed using magnetic resonance imaging when
clinical symptoms of PNI such as pain or paresthesias
are present. Review of imaging with a neuroradiol-
ogist is crucial, as radiographic detection of PNI can
be easily overlooked.
When treating patients with PNI using radiation,
we recommend targeting the local tumor bed, cranial
nerve pathways to the skull base, and nodal basins,
as PNI portends higher risks of failure in each of
these locations, especially in immunosuppressed
patients. Highly conformal radiation techniques
including IMRT with image-guided radiotherapy
are warranted to maximize coverage of the targets
of interest and minimize dose to surrounding organs
at risk.
Clinically involved lymph nodes carry higher risks
of failure, and multimodality therapy including
surgery (for primary and nodal basins) and adjuvant
radiation, is indicated. In another study from
Australia, improved 5-year disease-free survival
(74% vs 34%; P = .001) and 5-year overall survival
(66% vs 27%; P = .003) was seen in patients treated
with resection of the primary tumor and neck
dissection followed by postoperative RT compared
with those treated with surgery alone.7
Emerging data suggest that some HNCSCCs
behave quite aggressively in immunosuppressed
patients. These cancers are more likely to demon-
strate multifocality, PNI, and deep infiltration than in
immunocompetent patients, and some investigators
recognize inferior outcomes in these patients, even
with aggressive multimodality treatment.8,9 We
found a 2-year recurrence-free survival rate of 48%
in the immunosuppressed population compared
with 73% in the nonimmunosuppressed population
for patients with locally advanced HNCSCC treated
with resection and adjuvant radiotherapy.10 As such,
we often favor comprehensive treatment for these
patients, including targeting nodal levels at risk and
the course of the involved nerve, as we did in this
patient.In our practice, we recommend adjuvant radiation
for immunosuppressed patients with resected SCC if
they have de novo T3 or T4 disease, node-positive
disease, or any T1 to T2N0 disease with PNI (aside
from unifocal involvement of a small unnamed
nerve), or any recurrent disease. A combination of
other high-risk features, such as size greater than
2 cm, poorly differentiated or spindle cell histology,
or ear or lip primary tumor, can also play a role in
favoring adjuvant RT, especially in these higher-risk
patients.
This case highlights the importance of a multidis-
ciplinary approach to the immunosuppressed pa-
tient with HNCSCC. Radiotherapy plays an important
part in treating these high-risk patients. Further work
is needed to better risk stratify patients for intensified
adjuvant therapies.REFERENCES
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